Targets › DDC
3 programs from 3 companies in 5 trials: 3 Phase 4, 1 Phase 2, 1 Phase 1; Metabolic and endocrine, Neurology, Psychiatry; next expected readout Aug 2027.
Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine and L-5-hydroxytryptophan to serotonin. (UniProt, P20711)
Open in Phaseline: the race on DDC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Impax Laboratories | Carbidopa DOPA decarboxylase inhibitor | DDC | Phase 4 | Parkinson Disease; Anhedonia | – |
| PTC Therapeutics | Eladocagene Exuparvovec DDC exogenous gene | DDC | Phase 2 | AADC Deficiency | Apr 2028 |
| Krzysztof Bankiewicz | AAV2-hAADC Adeno-associated virus serotype 2 expressing human aromatic L-amino acid decarboxylase | DDC | Phase 1 | AADC Deficiency | Aug 2027 |
AADC Deficiency (2) Parkinson Disease (2) Anhedonia (1)
other (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.